Inclusion Criteria:  Participants with certain genetic predisposition to non-alcoholic fatty liver disease (NAFLD) determined at screening Presence of liver steatosis at screening Participants on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications must be on stable dose(s) for at least 4 weeks prior to screening Weight stable defined as no more than 5% body weight loss or gain within 3 months prior to screening and no more than 5% body weight loss or gain from screening to randomization  Exclusion Criteria:  Known allergies, hypersensitivity, or intolerance to JNJ-75220795 or its excipients History of hepatitis B surface antigen (HbsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HbsAg or anti-HCV at screening History of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening